Sekar Kathiresan - Jan 4, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Jan 4, 2022
Transactions value $
-$72,014
Form type
4
Date filed
1/6/2022, 03:36 PM
Previous filing
Dec 29, 2021
Next filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $2.6K +1.87K +0.46% $1.39* 408K Jan 4, 2022 Direct
transaction VERV Common Stock Sale -$74.6K -1.87K -0.46% $39.90 407K Jan 4, 2022 Direct F1
holding VERV Common Stock 81K Jan 4, 2022 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 81K Jan 4, 2022 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -1.87K -0.69% $0.00 267K Jan 4, 2022 Common Stock 1.87K $1.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021.
F2 The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.